專注於創新生物打印技術和生物墨水的開發和商業化的CELLINK今天宣布，該公司將與阿斯特捷利康藥廠（AstraZeneca）合作，提供先進的3D生物打印肝臟類器官，用於心血管，腎臟和代謝性疾病的藥物研發。

3D生物打印已成為一種有用的技術，可以概括天然組織的微環境，從而可以將多個細胞精確地打印到預定位置。

CELLINK在阿斯利康位於瑞典哥德堡的BioVentureHub設有研發實驗室。這項新的合作將利用CELLINK的創新且正在申請專利的生物墨水，Extra Cellular Matrix和層粘連蛋白為基礎的生物墨水，使人體細胞能夠像在人體中那樣生長和發揮作用。

CELLINK, focused on the development and commercialization of innovative bioprinting technologies and bioinks, announced today that the company will collaborate with AstraZeneca to provide advanced 3D-bioprinted liver organoids for drug discovery purposes in cardiovascular, renal and metabolic diseases.

In tissue engineering, the need for assembly of three-dimensional (3D) tissues is important. 3D-bioprinting has emerged as a useful technology to recapitulate the microenvironment of native tissue, allowing for precise printing of multiple cells into a pre-defined position.

CELLINK has an R&D lab in AstraZeneca’s BioVentureHub in Gothenburg, Sweden. The new collaboration will leverage CELLINK’s innovative and patent-pending bioink, Extra Cellular Matrix and Laminin based bioinks, which enables human cells to grow and function as they would in the human body.